Ligand Pharmaceuticals (LGND) Says Glaxo (GSK) Submits Regulatory Apps for Promacta/Revolade

May 30, 2012 10:17 AM EDT Send to a Friend
Get Alerts LGND Hot Sheet
Trade LGND Now!
Join SI Premium – FREE
Ligand Pharmaceuticals (Nasdaq: LGND) partner GlaxoSmithKline plc (NYSE: GSK) has submitted regulatory applications in the United States and European Union related to eltrombopag (Promacta/Revolade) and its use to increase platelet counts in patients with chronic hepatitis C virus infection and low platelets (thrombocytopenia), specifically:
  • A supplemental New Drug Application to the US Food and Drug Administration for Promacta (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and to optimize interferon-based therapy.

  • A variation to the Marketing Authorization Application to the European Medicines Agency for Revolade (eltrombopag) as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection to enable the initiation of interferon-based therapy and during interferon-based therapy.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment